The Inland Northwest’s Leader in Movement Disorder Research

Bringing experimental therapeutics to Spokane, with over 50 successful clinical trials completed since 2017.

Contact Us

Diseases We Study

  • Empty white sheet of paper with no visible objects or text.

    Parkinson's Disease

  • Line drawing of a brain with a sun and cloud symbols, representing thinking or mental health.

    Huntington's Disease

  • Illustration of a hand giving a high five with animated lines indicating motion for emphasis.

    Essential Tremor

  • Abstract black and white graphic of a brain with dotted patterns.

    Multiple System Atrophy (MSA)

  • White abstract line drawing of a cat on a black background.

    Dystonia

  • A blank, white, empty page with no visible objects or details.

    Ataxia

Collection of purple-topped vials in a white tray on a black surface, with yellow and white lab equipment visible in the background.

Our Trials

  • Actively recruiting participants with movement disorders to participate in clinical trials.

  • Conducting clinical studies to advance research in Parkinson’s disease, Huntington’s disease, Essential Tremor, MSA, Ataxia, and other movement and movement disorders.

  • Collaborating with national and global initiatives to focus on unmet clinical needs of patients living with movement disorders

Find a Clinical Trial
 

Our clinic is conveniently located just off I-90 in Spokane, Washington.

Featured Trials

Annovis - ANVS-25002 PD OLE

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Learn more

Vima - VIM0423-201 Stride

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.

The main objectives of this clinical trial are to determine the following: Does VIM0423 therapy improve dystonia symptoms compared to placebo? Is VIM0423 well tolerated in individuals with isolated dystonia? anf do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Learn more

Our Leadership

  • Smiling man in white medical coat with embroidered name, standing against plain white background.

    Jason Aldred, M.D., FAAN

    Dr. Jason Aldred, MD, FAAN, is a board-certified neurologist with specialized fellowship training in Parkinson's disease & movement disorders. He serves as the Principal Investigator for all clinical trials at our site. Dr. Aldred is a credentialed investigator with major research groups, ensuring the proper and ethical conduct of our studies.

  • Headshot of a smiling man with ginger hair, beard, wearing a blazer, shirt, and sweater, against a plain white background.

    Michael Dauer, MS, MBA

    Mike brings over 16 years of experience leading research and diagnostic teams at institutions like the University of Washington and Adaptive Biotechnologies. He oversees INWR’s daily operations and long-term strategy, ensuring high-quality trial execution, team support, and excellent sponsor collaboration.

Our Team

“Participating in an INWR trial gave me hope and helped contribute to finding a cure for people with Parkinson’s disease.”

— Parkinson’s Participant